抄録 Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is
generally used for booster vaccination of infants in Europe and the United States to avoid …

Background Incidence of whooping cough is increasing in Korea. Since 2011, occurrence
among adolescents and adults has risen putting vulnerable neonates at risk. National …

Four vaccines containing diphtheria and tetanus toxoids and acellular pertussis vaccine
(DTaP) are currently licensed in the United States for use among infants and young children …

The number of pertussis cases in Japan has decreased dramatically following the
nationwide use of an acellular pertussis vaccine combined with diphtheria-tetanus toxoids …

BACKGROUND: Pre-licensure clinical trials for two US licensed tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis (Tdap) vaccines did not reveal any major safety …

In Japan, the morbidity rate for pertussis per 100,000 population was 147.6 in 1950 when
whole cell pertussis vaccine was introduced but dropped to 0.2 in 1972 when routine …

In light of waning immunity to pertussis following receipt of tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis (Tdap) vaccine, maintaining protection may require …

A double blind, randomized, controlled trial compared the safety and immunogenicity of an
acellular pertussis vaccine formulated at Lederle using the Takeda acellular pertussis …

An observational post-licensure (Phase IV) retrospective large-database safety study was
conducted at Kaiser Permanente, a US integrated medical care organization, to assess the …

Diphtheria-tetanus-acellular pertussis (DTaP) vaccination must currently be administered
three times starting at 2 months of age, at intervals of two months, with the first and second …